185 related articles for article (PubMed ID: 24173497)
1. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.
Henriques de Figueiredo B; Zacharatou C; Galland-Girodet S; Benech J; De Clermont-Gallerande H; Lamare F; Hatt M; Digue L; De Mones del Pujol E; Fernandez P
Strahlenther Onkol; 2015 Mar; 191(3):217-24. PubMed ID: 25245468
[TBL] [Abstract][Full Text] [Related]
3. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
6. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
[TBL] [Abstract][Full Text] [Related]
8. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
[TBL] [Abstract][Full Text] [Related]
10. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
11. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
12. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.
Arens AI; Troost EG; Hoeben BA; Grootjans W; Lee JA; Grégoire V; Hatt M; Visvikis D; Bussink J; Oyen WJ; Kaanders JH; Visser EP
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):915-24. PubMed ID: 24346414
[TBL] [Abstract][Full Text] [Related]
13. Tumor volume delineation in head and neck cancer with 18-fluor-fluorodeoxiglucose positron emission tomography: adaptive thresholding method applied to primary tumors and metastatic lymph nodes.
Perez-Romasanta LA; Bellon-Guardia M; Torres-Donaire J; Lozano-Martin E; Sanz-Martin M; Velasco-Jimenez J
Clin Transl Oncol; 2013 Apr; 15(4):283-93. PubMed ID: 22865325
[TBL] [Abstract][Full Text] [Related]
14. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
Schütze C; Bergmann R; Brüchner K; Mosch B; Yaromina A; Zips D; Hessel F; Krause M; Thames H; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
Radiother Oncol; 2014 Apr; 111(1):81-7. PubMed ID: 24636842
[TBL] [Abstract][Full Text] [Related]
15. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
16. Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?
Abolmaali N; Haase R; Koch A; Zips D; Steinbach J; Baumann M; Kotzerke J; Zöphel K
Nuklearmedizin; 2011; 50(1):22-7. PubMed ID: 21165537
[TBL] [Abstract][Full Text] [Related]
17. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
18. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
Jansen JF; Schöder H; Lee NY; Wang Y; Pfister DG; Fury MG; Stambuk HE; Humm JL; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1403-10. PubMed ID: 19906496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
